Home/Filings/4/0001415889-22-012324
4//SEC Filing

Javitt Jonathan C 4

Accession 0001415889-22-012324

CIK 0001719406other

Filed

Dec 8, 7:00 PM ET

Accepted

Dec 9, 4:33 PM ET

Size

6.7 KB

Accession

0001415889-22-012324

Insider Transaction Report

Form 4
Period: 2022-12-07
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
  • Sale

    Common Stock, par value $0.001 per share

    2022-12-07$1.00/sh400,000$400,00012,899,997 total(indirect: By Trust)
Holdings
  • Common Stock, par value $0.001 per share

    146,332
  • Common Stock, par value $0.001 per share

    (indirect: By Trust)
    1,422,000
Footnotes (3)
  • [F1]Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc. Purchaser has agreed to hold the shares for a period of one year.
  • [F2]Held by the Jonathan Javitt Living Trust. The Reporting Person is a trustee of the Trust.
  • [F3]Held by the Javitt 2012 Irrevocable Dynasty Trust. The Reporting Person is the grantor of the Trust.

Issuer

NRX Pharmaceuticals, Inc.

CIK 0001719406

Entity typeother

Related Parties

1
  • filerCIK 0001303782

Filing Metadata

Form type
4
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 4:33 PM ET
Size
6.7 KB